Short Interest in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Decreases By 29.3%

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBYGet Free Report) saw a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 135,900 shares, a drop of 29.3% from the August 15th total of 192,200 shares. Based on an average daily volume of 286,900 shares, the days-to-cover ratio is presently 0.5 days.

NovaBay Pharmaceuticals Stock Performance

NBY remained flat at $0.47 during trading on Friday. 81,222 shares of the company’s stock were exchanged, compared to its average volume of 236,330. The company has a market capitalization of $2.00 million, a price-to-earnings ratio of -0.05 and a beta of 2.82. NovaBay Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $19.57.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBYGet Free Report) last announced its earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($1.37) earnings per share for the quarter. The company had revenue of $2.40 million during the quarter. NovaBay Pharmaceuticals had a negative return on equity of 146.20% and a negative net margin of 79.70%. As a group, research analysts forecast that NovaBay Pharmaceuticals will post -2.54 EPS for the current year.

NovaBay Pharmaceuticals Company Profile

(Get Free Report)

NovaBay Pharmaceuticals, Inc develops and sells eyecare and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; Avenova Eye Health Support antioxidant-rich oral supplements; Avenova Lubricating Eye Drops for instant relief; NovaWipes by Avenova; Avenova WarmEye Compress to soothe the eyes; and the i-Chek by Avenova to monitor physical eyelid health.

Featured Stories

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.